We are developing novel siRNA therapies for the treatment of cardiovascular diseases, addressing a potential market value of over 10 billion US dollars.
first-in-class
best-in-classSRSD107
FXI
SRSD101
PCSK9
SRSD216
Target C
SRSD131
Target D
SRSD158
Target E
SRSD229
Target F
SRSD230
Target G
SRSD258
Target H
Sirius Therapeutics, Inc., all rights reserved
为了更好的呈现效果，移动端请竖屏浏览
